Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 38.20 NOK
Change Today -1.30 / -3.29%
Volume 2.5K
PHO On Other Exchanges
As of 6:46 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

photocure asa (PHO) Snapshot

38.50 NOK
Previous Close
39.50 NOK
Day High
38.80 NOK
Day Low
38.10 NOK
52 Week High
05/11/15 - 44.00 NOK
52 Week Low
11/4/14 - 17.70 NOK
Market Cap
Average Volume 10 Days
-0.68 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for PHOTOCURE ASA (PHO)

Related News

No related news articles were found.

photocure asa (PHO) Related Businessweek News

No Related Businessweek News Found

photocure asa (PHO) Details

Photocure ASA engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment. The company markets Hexvix/Cysview for improved detection and management of bladder cancer. Its products pipeline includes Visonac that has completed Phase 2b study for the treatment of moderate to severe acne; Cevira, which has completed Phase 2b study for the treatment of human papilloma virus disease and precancerous lesions of the cervix; and Lumacan that is under Phase 1/2 development for the detection of colorectal cancer. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. It operates in Norway, Sweden, Denmark, Finland, and the United States. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

47 Employees
Last Reported Date: 04/9/15
Founded in 1997

photocure asa (PHO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

photocure asa (PHO) Key Developments

Juno to Distribute Photocure's Bladder Cancer Drug in Australia and New Zealand

Photocure ASA has partnered with Juno Pharmaceuticals for distribution of Hexvix, which is developed for the diagnosis and management of bladder cancer, in Australia and New Zealand. Under the terms of the agreement, Photocure will receive 500,000 in milestone payments for the rights to Hexvix in the territory, of which Photocure has received 250,000. Juno, who will fund all costs to secure regulatory approval, will begin the filing process immediately. During the review process, Juno Pharmaceuticals will initiate the preparations for the launch of Hexvix in Australia and New Zealand.

PhotoCure ASA Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

PhotoCure ASA reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were NOK 29.6 million against NOK 20.7 million a year ago. Operating loss was NOK 7.2 million against NOK 13.7 million a year ago. Loss before tax was NOK 7.0 million against NOK 13.0 million a year ago. Net loss share, diluted was NOK 0.51 against NOK 0.61 a year ago. Net cash flow used in from operations was NOK 11.897 million against NOK 18.662 million a year ago. Intangible asset investment was NOK 5.308 million. Machinery & equipment investment was NOK 0.236 million against NOK 0.090 million a year ago.

PhotoCure ASA Approves Amendment to Articles of Association

PhotoCure ASA announced that at its annual general meeting held on April 30, 2015, approved amendment of the company's articles of association.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHO:NO 38.20 NOK -1.30

PHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHO.
View Industry Companies

Industry Analysis


Industry Average

Valuation PHO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOCURE ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at